KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Amortization of Deferred Charges (2020 - 2025)

Historic Amortization of Deferred Charges for Esperion Therapeutics (ESPR) over the last 6 years, with Q3 2025 value amounting to $4.6 million.

  • Esperion Therapeutics' Amortization of Deferred Charges rose 92460.85% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year increase of 42122.94%. This contributed to the annual value of $1.5 million for FY2024, which is 1172.66% down from last year.
  • Latest data reveals that Esperion Therapeutics reported Amortization of Deferred Charges of $4.6 million as of Q3 2025, which was up 92460.85% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Amortization of Deferred Charges registered a high of $4.6 million during Q3 2025, and its lowest value of $172000.0 during Q4 2024.
  • In the last 5 years, Esperion Therapeutics' Amortization of Deferred Charges had a median value of $417000.0 in 2023 and averaged $811736.8.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first crashed by 7662.26% in 2021, then soared by 92460.85% in 2025.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Amortization of Deferred Charges stood at $407000.0 in 2021, then grew by 1.72% to $414000.0 in 2022, then rose by 4.11% to $431000.0 in 2023, then crashed by 60.09% to $172000.0 in 2024, then surged by 2562.79% to $4.6 million in 2025.
  • Its Amortization of Deferred Charges was $4.6 million in Q3 2025, compared to $3.7 million in Q2 2025 and $699000.0 in Q1 2025.